Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$16.25 USD
-1.27 (-7.25%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $16.26 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Stoke Therapeutics, Inc. [STOK]
Reports for Purchase
Showing records 81 - 92 ( 92 total )
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
From TINA to Cash Is King and Other Musings
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Runners up Is the New Killing It, and Other Tidbits
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Let?s Caucus, or Never Again; In an Otherwise Ho-Hum Earnings Week
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2020 Catalyst Calendar and Top Picks Across Mid, Small, and Micro Caps
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiating coverage at OUTPERFORM, $31 price target
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
All Set for 1Q20 IND With Additional Boost to Data Package
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Recap STK-001, 1Q20 IND the Next Milestone
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Exploiting Haploinsufficiencies as a Conduit to a Disease Modifying Treatment for Dravet; Initiating With a Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D